Trends in the proportion (%) of antimicrobial-resistant Escherichia coli[the proportion of antimicrobial resistance in humans]
![Trends in the proportion (%) of antimicrobial-resistant Escherichia coli[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/0101Escherichia-coliã®èæ§çã®æ¨ç§»-G.png)
A statistical information site that deepens
the understanding of AMR (drug resistance) and one health
A statistical information site that deepens
the understanding of AMR (drug resistance) and one health
![Trends in the proportion (%) of antimicrobial-resistant Klebsiella pneumoniae[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/0201Klebsiella-pneumoniaeã®èæ§çã®æ¨ç§»-G.png)
![Trends in the proportion (%) of antimicrobial-resistant Enterobacter cloacae[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/0301Enterobacter-cloacaeã®èæ§çã®æ¨ç§»-G.png)
![Trends in the proportion (%) of antimicrobial-resistant Klebsiella (Enterobacter) aerogenes[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/0401KlebsiellaEnterobacter-aerogenesã®èæ§çã®æ¨ç§»-G.png)
![Trends in the proportion (%) of antimicrobial-resistant Pseudomonas aeruginosa[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/0501Pseudomonas-aeruginosaã®èæ§çã®æ¨ç§»-G.png)
![Trends in the proportion (%) of antimicrobial-resistant Acinetobacter spp.[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/0601Acinetobacter-spp.ã®èæ§çã®æ¨ç§»-G.png)
![Trends in the proportion (%) of methicillin-susceptible Staphylococcus aureus (MSSA)[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/0701Methicillin-susceptible-Staphylococcus-aureusMSSAèæ§çã®æ¨ç§»-G.png)
![Trends in the proportion (%) of methicillin-resistant Staphylococcus aureus (MRSA)[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/0801Methicillin-resistant-Staphylococcus-aureusMRSA-ã®èæ§çã®æ¨ç§»-G.png)
![The proportion (%) of patients with MRSA among all patients with Staphylococcus aureus (S. aureus) All participating medical institutions[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/0901MRSAåé¢æ£è
ã®å
¨Staphylococcus-aureusS.-aureusåé¢æ£è
ã«å-ããå²å-G.png)
![The proportion (%) of patients with MRSA among all patients with Staphylococcus aureus (S. aureus) Participating medical institutions with 200 or more beds[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2019/03/0902MRSAåé¢æ£è
ã®å
¨Staphylococcus-aureusS.-aureusåé¢æ£è
ã«å-ããå²å-G.png)
![The proportion (%) of patients with MRSA among all patients with Staphylococcus aureus (S. aureus) Participating medical institutions with fewer than 200 beds[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2019/03/0903MRSAåé¢æ£è
ã®å
¨Staphylococcus-aureusS.-aureusåé¢æ£è
ã«å-ããå²å-G.png)
![Trends in the proportion (%) of antimicrobial-resistant Enterococcus faecalis[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/1001Enterococcus-faecalisã®èæ§çã®æ¨ç§»-G.png)
![Trends in the proportion (%) of antimicrobial-resistant Enterococcus faecium[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/1101Enterococcus-faeciumã®èæ§çã®æ¨ç§»-G.png)
![Trends in the proportion (%) of antimicrobial-resistant Streptococcus pneumoniae (CSF specimens)[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/1201Streptococcus-pneumoniaeé«æ¶²æ¤ä½ã®èæ§çã®æ¨ç§»-G.png)
![Trends in the proportion (%) of antimicrobial-resistant Streptococcus pneumoniae (non-CSF specimens)[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/1301Streptococcus-pneumoniaeé«æ¶²æ¤ä½ä»¥å¤ã®èæ§çã®æ¨ç§»-G.png)
![The proportion (%) of antimicrobial-resistant Campylobacter jejuni isolated from diarrhea cases[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/1601æ£çºä¸ç¢çç±æ¥Campylobacter-jejuniã®èæ§ç-G.png)
![The proportion (%) of antimicrobial-resistant Campylobacter coli isolated from diarrhea cases[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/1701æ£çºä¸ç¢çç±æ¥Campylobacter-coliã®èæ§ç-G-1.png)
![The proportion (%) of antimicrobial-resistant non-typhoidal Salmonella spp. derived from patients[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/1901ããæçè
ç±æ¥non-typhoidal-Salmonella-spp.ã®èæ§ç-G.png)
![The proportion (%) of antimicrobial-resistant food-derived non-typhoidal Salmonella spp.[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/2001é£åç±æ¥non-typhoidal-Salmonella-spp.ã®èæ§ç-G.png)
![The proportion (%) of antimicrobial-resistant food-derived Salmonella Infantis (2015-2017)[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2019/03/2101é£åç±æ¥Salmonella-Infantisã®èæ§ç2015ï½2017-G.png)
![The proportion (%) of antimicrobial-resistant food-derived Salmonella Schwarzengrund (2015-2017)[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2019/03/2201é£åç±æ¥Salmonella-Schwarzengrundã®èæ§ç2015ï½2017-G.png)
![The proportion (%) of antimicrobial-resistant human-derived Salmonella Infantis (2015-2017)[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2019/03/2301ããç±æ¥Salmonella-Infantisã®èæ§ç2015ï½2017-G.png)
![The proportion (%) of antimicrobial-resistant human-derived Salmonella Enteritidis (2015-2017)[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2019/03/2401ããç±æ¥Salmonella-Enteritidisã®èæ§ç2015ï½2017-G.png)
![The proportion (%) of antimicrobial-resistant human-derived Salmonella Saintpaul (2015-2017)[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2019/03/2501ããç±æ¥Salmonella-Saintpaulã®èæ§ç2015ï½2017-G.png)
![The proportion (%) of antimicrobial-resistant human-derived Salmonella 4:i:- (2015-2017)[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2019/03/2601ããç±æ¥Salmonella-4i-ã®èæ§ç2015ï½2017-G.png)
![The proportion (%) of antimicrobial-resistant human-derived Salmonella Thompson (2015-2017)[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2019/03/2701ããç±æ¥Salmonella-Thompsonã®èæ§ç2015ï½2017-G.png)
![Resistance rates among Salmonella Infantis, Salmonella Schwarzengrund, and Salmonella Manhattan detected in humans and food (2015-2017) (%)[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2019/03/2801Salmonella-InfantisSalmonella-SchwarzengrundSalmonella-Manhattanã®èæ§ç2015ï½2017-G.png)
![The proportion (%) of antimicrobial-resistant Neisseria gonorrhoeae[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/2311Neisseria-gonorrhoeaeã®èæ§ç-G.png)
![The proportion (%) of antimicrobial-resistant Salmonella Typhi[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/2411Salmonella-Typhiã®èæ§ç-G.png)
![The proportion (%) of antimicrobial-resistant Salmonella Paratyphi A[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/2511Salmonella-Paratyphi-Aã®èæ§ç-G.png)
![The proportion (%) of antimicrobial-resistant Shigella spp.[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/2611Shigella-spp.ã®èæ§ç-G.png)
![Newly Notified Patients with Culture-positive Pulmonary Tuberculosis: Trends in Drug Susceptibility at the Time of Notification[the proportion of antimicrobial resistance in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/2711æ°è¦èºçµæ-¸å¹é¤é½æ§æ£è
æ°ï¼ç»é²æè¬å¤æåæ§ã®æ¨ç§»-G.png)
![Serotypes of human- and food-derived non-typhoidal Salmonella spp.[bacterial infection in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/1801ããåã³é£åç±æ¥non-typhoidal-Salmonella-spp.ã®è¡æ¸
å-G.png)
![Number of cases reported for diseases subject to notifiable disease surveillance[bacterial infection in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/1401å
¨æ°ææ¡å¯¾è±¡ç¾æ£ã®å-±åæ°æ¨ç§»-G.png)
![Number of cases reported for diseases reportable from designated sentinel sites[bacterial infection in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/1501åºå¹¹å®ç¹å»çæ©é¢ããã®å±åºå¯¾è±¡ç¾æ£ã®æ¨ç§»-G.png)
![The trend of reported SSI cases[bacterial infection in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/2811SSIå
¨æè¡ææåè¨ã®çºçç¶æ³ã®æ¨ç§»-G.png)
![The trend of incidence rates of ventilator-associated pneumonia at ICU[bacterial infection in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/2901ICUã«ããã人工å¼å¸å¨é¢é£èºçã®ææççºçç¶æ³ã®æ¨ç§»-G.png)
![The trend of incidence rates of urinary tract infection at ICU[bacterial infection in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/2902ICU-ã«ãããå°¿è·¯ææççºçç¶æ³ã®æ¨ç§»-G.png)
![The trend of incidence rates of catheter-related bloodstream infection at ICU[bacterial infection in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/2903ICU-ã«ãããã«ãã¼ãã«é¢é£è¡æµææççºçç¶æ³ã®æ¨ç§»-G.png)
![Trends in the proportion (%) of IPM and MEPM-resistant Escherichia coli and parenteral Carbapenems consumption calculated from the sales[the proportion of antimicrobial resistance and antimicrobial consumption in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/0151Escherichia-coliã®IPMã»MEPMèæ§çã®æ¨ç§»ã¨è²©å£²é-G.png)
![Trends in the proportion (%) of LVFX-resistant Escherichia coli and oral Fluoroquinolones consumption calculated from the sales data[the proportion of antimicrobial resistance and antimicrobial consumption in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/0152Escherichia-coliã®LVFXèæ§çã®æ¨ç§»ã¨è²©å£²é-G.png)
![Trends in the proportion (%) of LVFX-resistant Escherichia coli and parenteral Fluoroquinolones consumption calculated from the sales data[the proportion of antimicrobial resistance and antimicrobial consumption in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/0153Escherichia-coliã®LVFXèæ§çã®æ¨ç§»ã¨è²©å£²é-G.png)
![Trends in the proportion (%) of IPM and MEPM-resistant Klebsiella pneumoniae and parenteral Carbapenems consumption calculated from the sales data[the proportion of antimicrobial resistance and antimicrobial consumption in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/0251Klebsiella-pneumoniaeã®IPMã»MEPMèæ§çã®æ¨ç§»ã¨è²©å£²é-G.png)
![Trends in the proportion (%) of IPM and MEPM-resistant Pseudomonas aeruginosa and parenteral Carbapenems consumption calculated from the sales data[the proportion of antimicrobial resistance and antimicrobial consumption in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/0551Pseudomonas-aeruginosaã®IPMã»MEPMèæ§çã®æ¨ç§»ã¨è²©å£²é-G.png)
![Trends in the proportion of (%) of patients with MRSA among all patients with Staphylococcus aureus (S. aureus) and oral penicillins consumption caluated from the sales data[the proportion of antimicrobial resistance and antimicrobial consumption in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/0951MRSAåé¢æ£è
ã®å
¨S.-aureusåé¢æ£è
ã«å-ããå²åã¨è²©å£²é-G.png)
![Trends in the proportion of (%) of patients with MRSA among all patients with Staphylococcus aureus (S. aureus) and parental penicillins consumption calculated from the sales data[the proportion of antimicrobial resistance and antimicrobial consumption in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/0952MRSAåé¢æ£è
ã®å
¨S.-aureusåé¢æ£è
ã«å-ããå²åã¨è²©å£²é-G.png)
![Trends in the proportion of (%) of patients with MRSA among all patients with Staphylococcus aureus (S. aureus) and oral Cephalosporins consumption calculated from the sales data[the proportion of antimicrobial resistance and antimicrobial consumption in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/0953MRSAåé¢æ£è
ã®å
¨S.-aureusåé¢æ£è
ã«å-ããå²åã¨è²©å£²é-G.png)
![Trends in the proportion of (%) of patients with MRSA among all patients with Staphylococcus aureus (S. aureus) and parental Cephalosporins consumption calculated from the data[the proportion of antimicrobial resistance and antimicrobial consumption in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/0954MRSAåé¢æ£è
ã®å
¨S.-aureusåé¢æ£è
ã«å-ããå²åã¨è²©å£²é-G.png)
![Trends in the proportion of (%) of patients with MRSA among all patients with Staphylococcus aureus (S. aureus) and oral Fluoroquinolones consumption calculated from the sales data[the proportion of antimicrobial resistance and antimicrobial consumption in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/0955MRSAåé¢æ£è
ã®å
¨S.-aureusåé¢æ£è
ã«å-ããå²åã¨è²©å£²é-G.png)
![Trends in the proportion of (%) of patients with MRSA among all patients with Staphylococcus aureus (S. aureus) and parental Fluoroquinolones consumption calculated from the sales data[the proportion of antimicrobial resistance and antimicrobial consumption in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/0956MRSAåé¢æ£è
ã®å
¨S.-aureusåé¢æ£è
ã«å-ããå²åã¨è²©å£²é-G.png)
![Trends in the proportion (%) of antimicrobial-resistant Streptococcus pneumoniae (CSF specimens) and oral penicillins consumption calculated from the sales data[the proportion of antimicrobial resistance and antimicrobial consumption in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/1251Streptococcus-pneumoniaeé«æ¶²æ¤ä½ã®èæ§çã®æ¨ç§»ã¨è²©å£²é-G.png)
![Trends in the proportion (%) of antimicrobial-resistant Streptococcus pneumoniae (CSF specimens) and parental penicillins consumption calculated from the sales data[the proportion of antimicrobial resistance and antimicrobial consumption in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/1252Streptococcus-pneumoniaeé«æ¶²æ¤ä½ã®èæ§çã®æ¨ç§»ã¨è²©å£²é-G.png)
![Trends in the proportion (%) of antimicrobial-resistant Streptococcus pneumoniae (non- CSF specimens) and oral penicillins consumption calculated from the sales data[the proportion of antimicrobial resistance and antimicrobial consumption in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/1351Streptococcus-pneumoniaeé«æ¶²æ¤ä½ä»¥å¤ã®èæ§çã®æ¨ç§»ã¨è²©å£²é-G.png)
![Trends in the proportion (%) of antimicrobial-resistant Streptococcus pneumoniae (non- CSF specimens) and parental penicillins consumption calculated from the sales data[the proportion of antimicrobial resistance and antimicrobial consumption in humans]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/1352Streptococcus-pneumoniaeé«æ¶²æ¤ä½ä»¥å¤ã®èæ§çã®æ¨ç§»ã¨è²©å£²é-G.png)
![Trends in the proportion (%) of ABPC-resistant Escherichia coli[the proportion of antimicrobial resistance in humans and animals]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/0131Escherichia-coliã®ABPCèæ§çã®æ¨ç§»-G.png)
![Trends in the proportion (%) of CEZ-resistant Escherichia coli[the proportion of antimicrobial resistance in humans and animals]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/0132Escherichia-coliã®CEZèæ§çã®æ¨ç§»-G.png)
![Trends in the proportion (%) of CTX-resistant Escherichia coli[the proportion of antimicrobial resistance in humans and animals]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/0133Escherichia-coliã®CTXèæ§çã®æ¨ç§»-G.png)
![Trends in the proportion (%) of Fluoroquinolones-resistant Escherichia coli[the proportion of antimicrobial resistance in humans and animals]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/0134Escherichia-coliã®Fluoroquinolonesèæ§çã®æ¨ç§»-G.png)
![The proportion (%) of antimicrobial-resistant non-typhoidal Salmonella spp. derived from human, food and animal slaughterhouses[the proportion of antimicrobial resistance in humans and animals]](https://amr-onehealth.ncgm.go.jp/en/wp-content/uploads/2018/03/1921Salmonella-spp.ããç±æ¥ï¼ããã¹ä»¥å¤ã®èæ§çã®æ¯è¼2015å¹´-G.png)